Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2026)

Cytosorbents filings provide 10 years of Asset Writedowns and Impairment readings, the most recent being -$136000.0 for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 31.31% to -$136000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $40000.0, a 65.22% decrease, with the full-year FY2025 number at $40000.0, down 65.22% from a year prior.
  • Asset Writedowns and Impairment hit -$136000.0 in Q4 2025 for Cytosorbents, down from -$77000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $641226.0 in Q4 2023 to a low of -$421057.0 in Q3 2022.
  • Median Asset Writedowns and Impairment over the past 5 years was $4013.5 (2021), compared with a mean of $40091.0.
  • Biggest five-year swings in Asset Writedowns and Impairment: crashed 6960.96% in 2022 and later soared 5760.47% in 2024.
  • Cytosorbents' Asset Writedowns and Impairment stood at -$6649.0 in 2021, then plummeted by 181.59% to -$18723.0 in 2022, then soared by 3524.8% to $641226.0 in 2023, then plummeted by 130.88% to -$198000.0 in 2024, then surged by 31.31% to -$136000.0 in 2025.
  • The last three reported values for Asset Writedowns and Impairment were -$136000.0 (Q4 2025), -$77000.0 (Q3 2025), and $251110.0 (Q2 2025) per Business Quant data.